

1 SAFETY PROFILE OF COVID-19 VACCINES IN PREGNANT AND POSTPARTUM WOMEN IN BRAZIL

2 Authors names: Yaping Qiao PhD*¹, Ariane de Jesus Lopes de Abreu MSc*², Carolina Zampirolli Dias
3 MSc², Xing Meng PhD¹, Rafaela Vansan Ferreira BSc², Ramon Gonçalves Pereira MSc², Guilherme Silva
4 Julian MSc², Weidong Yin MBA¹

5 * Y.P.Q. and A.J.L.A contributed equally to this article.

6 Affiliations and full addresses:

7 ¹ Sinovac Biotech Co, Ltd, Beijing, P.R. China; qiaoy6109@sinovac.com (Y.P.Q.); mengx@sinovac.com
8 (X.M.); yinwd@sinovac.com (W.D.Y.)

9 ² IQVIA Brazil, São Paulo 04719-002, SP, Brazil; ariane.dejesuslopesdeabreu@iqvia.com (A.J.L.A.);
10 carolina.zampirolli@iqvia.com (C.Z.D.); rafaela.ferreira@iqvia.com (R.V.F.); rpereira2@br.imshealth.com
11 (R.G.P.); guilherme.julian@iqvia.com (G.S.J.)

12

13 Corresponding Author:

14 Weidong Yin

15 Sinovac Biotech Co, Ltd, No. 39, Shangdi Xi Road, Haidian District, Beijing 100085, Beijing, P.R. China,
16 yinwd@sinovac.com

17

18 Abstract

19 **Background:** Although COVID-19 vaccines are currently under use in pregnant and postpartum women,
20 there is still lack of evidence regarding safety and effectiveness in these populations. This study aims to
21 describe the safety profile of COVID-19 vaccines in pregnant and postpartum women in the early stage
22 of vaccination campaign in Brazil. **Methods:** This is an observational cross-sectional study using data
23 from the Brazilian surveillance information system for adverse events (SI-EAPV) to characterize the
24 safety of COVID-19 vaccines available (Sinovac/Butantan, Pfizer/BioNTech, AstraZeneca and Janssen) in
25 Brazilian pregnant and postpartum women after receiving it from April to August 2021. A descriptive
26 analysis was performed to assess the frequency and incidence rate of the adverse events (AE) for
27 COVID-19 vaccines. **Results:** A total of 3,333 adverse events following COVID-19 immunization were
28 reported for the study population in the SIEAPV. The incidence of AE found was 309.4/100,000 doses
29 (95% CI 297.23, 321.51). Regarding the four vaccines available in the country, Sinovac/Butantan had the
30 lowest incidence (74.08/100,000 doses; 95% CI 63.47, 84.69). Systemic events were the most frequent
31 notified for the group (82.07%), followed by local (11.93%) and maternal (4.74%), being most of them
32 classified as non-severe (90.65%). **Conclusion:** A similar pattern of AE as stated in other studies was
33 found, with even better results for non-viral vector vaccines, corroborating to the recommendation of
34 vaccination for these groups. Even though, further studies appraising a longer observation time are still
35 needed to provide a broader safety aspect for the vaccines currently under use for this population.

36

37 Introduction

38 The Coronavirus disease 2019 (COVID-19) has been shown to be less lethal than previous coronavirus
39 diseases, although it is highly contagious. Also, a higher risk of severe disease has been associated with
40 aging and comorbidities.¹ Equally important increased risk has been noted in pregnant and postpartum
41 women, making them particularly vulnerable to COVID-19.¹ Studies have shown that, when compared to
42 non-pregnant, pregnant women might develop more severe symptoms, being at increased risk of
43 requiring hospitalization in intensive care unit, along with invasive ventilation, extra corporeal
44 membrane oxygenation and mortality.^{2,3} In Brazil, more than 18 thousand cases of severe acute
45 respiratory syndrome (SARS) by COVID-19 were recorded in pregnant and postpartum women, resulting
46 in almost 1,500 deaths by June 2021.⁴ Likewise, a 20% increase in maternal mortality rate was observed
47 in 2020.⁴

48 Until now, there is still lack of evidence regarding safety and efficacy of the vaccines in pregnant and
49 postpartum women, since they were not included in initial studies of COVID-19 vaccines.⁵ Even
50 though, considering their higher susceptibility to COVID-19, vaccination for this group has been
51 conducted by assessing risks and benefits.⁶ COVID-19 immunization started on January 2021 in Brazil
52 and, in March 2021, pregnant and postpartum women with comorbidities were defined as priority
53 group.⁷ In April 2021, Ministry of Health (MoH) recommended that this subgroup should be vaccinated,
54 as long as a careful assessment was carried out with the physician, regardless of the gestational age.⁷
55 Due to adverse events experience by this subgroup, in May 2021 vaccination was changed again only for
56 those women with comorbidity, and, in July 2021, changed to include the entire maternal population.⁷
57 Four COVID-19 vaccines were initially recommended - Sinovac/Butantan, Janssen, AstraZeneca and
58 Pfizer/BioNTech, although after May 2021 there was a recommendation to remain only
59 Sinovac/Butantan and Pfizer/BioNTech vaccines for this group^{8,9}

60 By November 2021, about 1,7 million doses have been administered in this group, with an estimative to
61 vaccinate more than 2,5 million pregnant and postpartum women in the country.^{8,10} Post authorization
62 safety studies are a way to provide more evidence for this population. However, up to now, there are
63 few evidence regarding the safety profile of those vaccines for pregnant and postpartum women from
64 real world evidence perspective, considering pharmacovigilance systems as main source of information,
65 especially for low and middle-income countries (LMIC), such as Brazil.¹¹ In that way, this study aims to
66 describe the incidence of adverse events (AE) reported by pregnant and postpartum women after
67 receiving vaccines approved for use in the early stage of vaccination campaign (April 2021 to August
68 2021) in Brazil.

69 Methods

70 Surveillance Systems and Covered Population

71
72 In Brazil, records of adverse events following immunization (AEFI) in vaccinated individuals in the public
73 services are made available by the General Coordination of the National Immunization Program (NIP).
74 The NIP is responsible for the registration, investigation and causality analysis of AEFI reported by the
75 public health system.¹² For this study we requested the SI-EAPV (AEFI Surveillance Information System)
76 dataset to the Brazilian MoH, using the Fala BR platform ([https://www.gov.br/acessoainformacao/pt-
77 br/falabr](https://www.gov.br/acessoainformacao/pt-br/falabr)).¹³ This system is linked to the national system for reporting AE related to the use of drugs and
78 vaccines in VigiMed, adopted at the end of 2018 by Anvisa, as a result of its partnership with the
79 Uppsala Monitoring Centre (UMC).¹⁴ The SI-EAPV has the purpose to systematically monitor the
80 notifications, investigate and consolidate data relating to AEFI occurring at the National, State, Regional,
81 Municipal and local levels, contributing to improve the safety in the use of immunizations, with a passive
82 surveillance approach. Following the stablished flow, during the COVID-19 pandemic, all AEFI related to
83 COVID-19 vaccines have been notified in SI-EAPV.¹⁵ To assess the total number of vaccines doses
84 administered in the country, the National Vaccination Campaign against COVID-19 database

85 (“*Campanha Nacional de Vacinação contra a COVID-19*”), from *OpenDatasus*, were used.¹⁶ This dataset
86 is updated daily and, for this study, we used data from 3 November 2021. Pregnant women were
87 identified in the datasets as those who reported to be pregnant at the time they received the vaccine
88 and postpartum were considered those women who reported to be breastfeeding in the SI-EAPV and
89 who declared to be at postpartum at the moment of the vaccination.

90 Registries of AEFI with more than 50% of variables with missing data were excluded from the study.
91 Quality check procedures within the dataset were performed; this led to the exclusion of São Paulo
92 State from the analysis to minimize potential selection and information bias since the data was
93 underreported.

94 Study setting and outcomes

95

96 We analyzed AEFI notifications reported by pregnant and postpartum women who received any COVID-
97 19 vaccine authorized and available in Brazil for use. AEFI could be reported as adverse event (AE) or
98 immunization error (IE), after receiving at least one dose of a COVID-19 vaccine, including: CoronaVac
99 (Sinovac/Butantan), Ad26.COV2.S (Janssen), ChAdOx1 nCoV-19 and BBV152 (AstraZeneca) and/ or
100 BNT162b2 (Pfizer/BioNTech).

101 Demographic characteristics were described according to the age, race/ethnicity, region of the country
102 where the notification was reported and the maternal situation of the woman. The AE were described
103 according to the type (local, systemic and maternal)¹⁷, severity (severe and non-severe) as well as the
104 case evolution (death, under investigation, cure without sequelae, unknown/ loss of follow-up and
105 under investigation). AE reported as “COVID-19”, “PCR positive to COVID-19” and the like were classified
106 as inconclusive and those reported as “vaccination error”, “inadvertent exposure to vaccine”,
107 “contraindication” was classified as inconsistent.

108 Additionally, considering that MoH changed the recommendation to vaccinate this groups only with
109 vaccines that do not contain viral vector, the same woman could have received different vaccines as first
110 and second dose.^{7,8}

111 Statistical Analysis

112 Description of AE notifications characteristics were performed for women reporting to be pregnant or at
113 postpartum after receiving a COVID-19 vaccine from April to August 2021. AE were presented as number
114 and frequency (%) for the outcomes of interest. The incidence rate (IR) of AE per 100,000 doses applied
115 was also estimated with 95% confidence interval (CI). IR was calculated dividing the number of AE
116 notified during the period of the study by the number of doses administered in the same group in the
117 same period. Data analyses were conducted using Python version 3.6.5 (Python Software Foundation).
118 Datasets used were public and anonymized, protecting the confidentiality and privacy of all patients.¹⁸
119 All activities were conducted according to the applicable federal laws.¹⁹

120 Results

121 From April to August 2021, a total of 3,333 AEFI reported by Brazilian pregnant and postpartum women
122 who received COVID-19 vaccines in the SI-EAPV were included in the study. Of those, 473 were from
123 women who received Sinovac/Butantan, 788 Pfizer/BioNTech, 2,016 AstraZeneca and 56 Janssen (Figure
124 1). AE was the most common reported AEFI by this population (74.59%). Regarding IE, they were
125 reported in 25.29% of the notifications, being more frequent among pregnant and postpartum women
126 who received Sinovac/Butantan and Pfizer/BioNTech vaccines (60.47% and 73.21%, respectively)
127 (Supplementary material 1).

128 Adverse Events reported in SIEAPV

129 AE notifications were more frequent among pregnant and postpartum women aged 20 to 35 years old,
130 with a mean age of 28.56 (Standard Deviation 7.2), who reported as white (42.84%) and brown (36.89%)

131 (Table 1). From a regional perspective, even excluding the state of São Paulo, the South (34.31%) and
132 Southeast (33.79%) regions had most part of the notification from pregnant and postpartum women,
133 although it changed according to the vaccine received: for Sinovac/Butantan the highest were noted in
134 the South (40.64%), for Pfizer/BioNTech in the Southeast (45.45%), for AstraZeneca in the South
135 (35.75%) and for Janssen in the Northeast (46.67%). According to the maternal situation, few women
136 reported as being at postpartum (1.53%) and the distribution within the three trimesters of pregnancy
137 were similar (25.34% in the first, 30.01% in the second and 32.82% in the third trimester of pregnancy)
138 (Table 1).

139 Incidence of adverse events

140 The overall incidence of AE among pregnant and postpartum women was 309.4 / 100,000 doses of
141 vaccines administered (95% CI 297.23, 321.51). In the analysis according to the maternal situation, IR by
142 pregnant women was 404.3 / 100,000 doses (95% CI 388.75, 420.75) and by postpartum 19.6 / 100,000
143 doses (95% CI 13.47, 25.78). Regarding the four vaccines available in the country, Sinovac/Butantan
144 vaccine had the lowest IR (74.08 / 100,000 doses; 95% CI 63.47, 84.69) (Table 2).

145 Stratifying the AE according to type, among pregnant women, systemic events were the most frequent
146 notified (82.03%), followed by local (11.93%) and maternal (4.78%), being most of them classified as
147 non-severe (90.65%) (Supplementary appendix 2). Also, the IR of systemic events in the Brazilian
148 pregnant women was the highest (249.88/ 100,000 doses: 95% CI 238.97, 260.8). Maternal AE IR was
149 14.56/ 100,000 doses (95% CI 11.92, 17.2) (Table 3).

150 The most common maternal AE notified by pregnant and postpartum women included spontaneous
151 abortion (2.37%) pregnancy bleeding (0.76%) and neonatal death (0.52%). Among the non-maternal AE,
152 headache (18.54%), fever (13.79%), myalgia (10.30%) and pain (7.60%) were the most reported. The

153 most frequent AE were similar among the four vaccines, except for pain, which was less frequent
154 reported for those who received Sinovac/Butantan vaccine (Table 4).

155 Regarding the case evolution of the events, 53.30% were missing and 30.85% reported as being cured
156 without sequelae (Supplementary material 3).

157 Discussion

158

159 In the COVID-19 pandemic reality, despite the recognition of the need for inclusion of pregnant and
160 postpartum women in clinical trials, the speed at which the COVID-19 vaccines were developed, and
161 trials conducted precluded inclusion of them.²⁰ In that sense, post authorization safety studies are a way
162 to provide more evidence for this population.

163 Using surveillance data, we found more than 3,000 events notifications by pregnant and postpartum
164 women after receiving at least one dose of a COVID-19 vaccine in the early stage of the campaign in
165 Brazil. AE were the most common, although for some vaccines IE were more frequent – which may
166 reflect the changes in recommendation to vaccinate this group disposed by the Brazilian MoH.^{8,21}

167 Concerning the frequency of AE, the distribution according to the age and race/ethnicity was similar
168 within all vaccines available. However, in a regional perspective, it differed as each region/state could
169 have differences in the cold chain distribution strategies.⁸ Among the maternal population, pregnant
170 women were responsible for most of the notifications reported in the period.

171 The overall incidence of AE found for this population was 309.4/ 100,000 doses. Although there is a lack
172 of evidence regarding the safety of these vaccines in the maternal population, our findings are in
173 accordance with the available literature for other studies that assessed safety of COVID-19 in different
174 populations groups. An epidemiological bulletin from the Brazilian MoH from January to February of

175 2021 showed a 350.9 AEFI notifications/ 100,000 doses of vaccines early administered in the Brazilian
176 population.²² Another study conducted in Minas Gerais state that assessed safety of COVID-19 vaccines
177 from January to March 2021 found an incidence rate of 777.12 AEFI per 100,000 doses applied, with
178 97% of them classified as non-severe AE.²³

179 In relation to the magnitude of our findings when compared to other vaccines recommended to
180 pregnant and postpartum women in Brazil, a study from Silveira IO *et al*, assessing adverse events from
181 the SI-EAPV database from 2015 to 2019 in Minas Gerais state, found an overall incidence of 76.9 AEFI
182 notifications/100,000 doses.²⁴ Findings related to race/ ethnicity, type of event and case evolution were
183 also similar to the patterns found in our results.²⁴

184 As for the systemic events found in our study, the most frequent types follow a similar pattern described
185 by Gattás VL, *et al* in relation to the ones found for influenza vaccine, which is recommended for any
186 gestational age in Brazil, as COVID-19 vaccines are.²⁵ Although we have not compared pregnant to non-
187 pregnant women, there are studies suggesting that the physiologic changes in pregnancy seems to not
188 materially affect non-maternal events.^{26,27}

189 Additionally, our study describes with more emphasis systemic events classified as maternal, showing an
190 incidence of 14.56 AE notifications/ 100,000 doses, of which spontaneous abortion was the most
191 frequent type of event (2.37%) and with differences in the frequency found for the different types of
192 vaccines available. Brazilian data up to 2019 showed a proportion of 3.4% of spontaneous abortion in
193 the country. Meanwhile, spontaneous abortion incidence in the literature varies from 6.5% to 21% of
194 pregnancies, and it is recognized as one of the most common complications during a pregnancy.²⁸⁻³⁰ In
195 addition, a study assessing safety of mRNA COVID-19 vaccines in pregnant population in the United
196 States assessed by the V-Safe pregnancy registry system found an overall frequency of spontaneous
197 abortion of 12.6% among pregnant women who received a COVID-19 vaccines.²⁶ Cardoso BB *et al*³¹,

198 however, argues that data on abortion and its complications may be incomplete in Brazil, since the
199 hospitalizations occurred due to an abortion is only one data source to estimate the total number of
200 abortions in the country.³¹

201 When comparing the different vaccines administered in this population in Brazil, we found that
202 Sinovac/Butantan and Pfizer/BioNTech vaccines had the lowest IR of AE, which is in line with MoH
203 recommendations to only administer them in pregnant and postpartum woman.^{8,32}

204 Our study has some limitations. The AEFI notifications used in this study are subject to limitations of
205 passive surveillance system. This means that each health level routinely and periodically sends
206 information about the events subject to surveillance at the immediately superior. In the same way, the
207 classifications in the database might be susceptible to the interpretation of the person filling out the
208 system, implying in the possibility of lack of uniformity in reporting the characteristics of the event and
209 in the place where the information is filled in the form of the surveillance system. Although these
210 systems generate valuable information regarding the description of the occurrence of adverse events,
211 they usually do not allow establishing causality between the occurrence of AEFI and the vaccine.^{11,33-35} In
212 that sense, our study is unable to evaluate AE outcomes that might occur in association with exposures
213 earlier in pregnancy or postpartum period.

214 Furthermore, the definition of postpartum women varied in the data sources used - which may
215 underestimate the incidence in this population. In the same direction, the Brazilian obstetric
216 observatory for COVID-19 has been showing that there are inconsistencies in the vaccination
217 information fulfilling, since they found pregnant and postpartum women of male sex, and AEFI notified
218 for COVID-19 vaccines administered previous to the vaccination campaign start and over 55 years old.⁴

219 Another potential limitation of our analyses is the underreporting of AE. SIEAPV is a passive surveillance
220 system. Underreporting can occur due to difficulties in the conclusion of cases investigations and in
221 adherence of the population to notify the events. In that sense, mild to moderate events might be more
222 underreported than severe that required hospitalization or more intensive care. On the other hand,
223 each of the four vaccines were available in different moments (Sinovac/Butantan and AstraZeneca since
224 January, Pfizer/BioNTech since May and Janssen since July 2021).⁸ The Janssen vaccine was first
225 provided to the population when there was already the recommendation not to vaccinate pregnant and
226 postpartum women with viral vector vaccines, which led to a small number of doses administered in this
227 population, hence, a low number of notifications up to the cut-off period of this study. In the same
228 sense, Sinovac/Butantan and AstraZeneca vaccines were available in the beginning of the campaign,
229 when only women with comorbidities were being vaccinated.⁸ Also, some of the AE presented in this
230 study might be still under investigation during the study period and might not have a final classification.

231 Nevertheless, our study allows a better understand of COVID-19 vaccines safety profile under a
232 vaccination campaign placed during a pandemic setting in a LMIC as Brazil. We found a similar pattern of
233 AE as stated in other studies, with even better results for non-viral vector vaccines, corroborating that
234 vaccination of this groups should continue as a priority. Further studies appraising a longer time for a
235 better understanding adverse events incidence in relation to second and booster doses and the
236 component of vaccine interchangeability are still needed to provide a broader safety aspect for the
237 vaccines currently under use for this population.

238

239 Contributors

240 AJLA, YPQ and GSJ conceptualized the study. RGP, RVF, AJLA and CZD analyzed the data. RGP and RVF
241 curated the data. AJLA, YPQ, CZD and GSJ wrote the first draft of the manuscript. YPQ, XM, WDY and
242 other authors reviewed and edited revisions of the manuscript, had full access to all the data in the
243 study, and had final responsibility for the decision to submit for publication.

244 Declaration of interests

245 RGP, RVF, AJLA, GSJ and CZD are employees of IQVIA Brazil which was contracted by Sinovac Life
246 Sciences to conduct the study.

247 YPQ, XM, WDY are employees of Sinovac Life Sciences.

248

249 Acknowledgments

250

251

References

- 252 1. Bchetnia M, Girard C, Duchaine C, Laprise C. Journal of Infection and Public Health The outbreak
253 of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the
254 current global status. J Infect Public Health [Internet] 2020;13(11):1601–10. Available from:
255 <https://doi.org/10.1016/j.jiph.2020.07.011>
- 256 2. Roggero P, Prefumo F, Silva M, et al. Maternal and Neonatal Morbidity and Mortality Among
257 Pregnant Women With and Without COVID-19 Infection The INTERCOVID Multinational Cohort
258 Study. 2021;1–10.
- 259 3. Rasmussen SA, Kelley CF, Jamieson DJ, Horton JP. Coronavirus Disease 2019 (COVID-19)
260 Vaccines and Pregnancy What Obstetricians Need to Know. 2021;137(3):408–14.
- 261 4. Rodrigues A, Lacerda L, Francisco R. Brazilian Obstetric Observatory. arXiv Prepr
262 2021;arXiv:2105:1–19.
- 263 5. Heath PT, Doare K Le, Khalil A. Inclusion of pregnant women in COVID-19 vaccine development.
264 Lancet Infect Dis [Internet] 2020;20(9):1007–8. Available from: [http://dx.doi.org/10.1016/S1473-](http://dx.doi.org/10.1016/S1473-3099(20)30638-1)
265 [3099\(20\)30638-1](http://dx.doi.org/10.1016/S1473-3099(20)30638-1)
- 266 6. Quintana SM. We have Vaccine for COVID-19! What to Recommend for Pregnant Women? Rev
267 Bras Ginecol e Obs 2021;43(2):81–3.
- 268 7. Brasil. Ministério da Saúde. NOTA TÉCNICA N° 2 / 2021-SECOVID / GAB / SECOVID / MS. 2021.
- 269 8. Brasil. Ministério da Saúde. Secretaria Extraordinária de Enfrentamento à COVID-19. PLANO
270 NACIONAL DE OPERACIONALIZAÇÃO DA VACINAÇÃO CONTRA A COVID-19. 11ª. Brasília/DF: 2021.
- 271 9. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Imunizações e

- 272 Doenças Transmissíveis. Nota técnica n° 651/2021-cgpn/deidt/svs/ms 1. 2021;4–7.
- 273 10. Rodrigues NB, McIntyre RS, Lipsitz O, et al. A simplified 6-Item clinician administered dissociative
274 symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine
275 infusions. *J Affect Disord* 2021;282:160–4.
- 276 11. Development P. Maternal Immunization Safety Monitoring in Low- and Middle-Income
277 Countries: A Roadmap for Program Development Building an approach that is practical ,.
- 278 12. Moura ADA, Rouberte ESC, Lima FET, Chaves CS, Canto SVE, Lima GG de. Sistema de Informação
279 de Eventos Adversos Pós-Vacinação (SI-EAPV): vantagens e desafios / Post-Vaccination Adverse
280 Event Information System (SI-EAPV): advantages and challenges. *Brazilian J Heal Rev*
281 2020;3(5):15610–22.
- 282 13. Fala.BR - Plataforma Integrada de Ouvidoria e Acesso à Informação [Internet]. Available from:
283 <https://www.gov.br/acessoainformacao/pt-br/falabr>
- 284 14. BRASIL. ANVISA. BOLETIM DE FARMACOVIGILÂNCIA N°11 [Internet]. 2020. Available from:
285 [https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/fiscalizacao-e-](https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/fiscalizacao-e-monitoramento/farmacovigilancia/boletins-de-farmacovigilancia/boletim-de-farmacovigilancia-no-11.pdf/view)
286 [monitoramento/farmacovigilancia/boletins-de-farmacovigilancia/boletim-de-farmacovigilancia-](https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/fiscalizacao-e-monitoramento/farmacovigilancia/boletins-de-farmacovigilancia/boletim-de-farmacovigilancia-no-11.pdf/view)
287 [no-11.pdf/view](https://www.gov.br/anvisa/pt-br/centraisdeconteudo/publicacoes/fiscalizacao-e-monitoramento/farmacovigilancia/boletins-de-farmacovigilancia/boletim-de-farmacovigilancia-no-11.pdf/view)
- 288 15. BRASIL. Ministério da Saúde. SISTEMA DE INFORMAÇÕES DO PROGRAMA NACIONAL DE
289 IMUNIZAÇÕES EVENTOS ADVERSOS PÓS-VACINAÇÃO: Manual do usuário. 2003.
- 290 16. Brasil. Ministério da Saúde. Campanha Nacional de Vacinação contra Covid-19 [Internet]. [cited
291 2021 Aug 5]; Available from: <https://opendatasus.saude.gov.br/fr/dataset/covid-19-vacinacao>
- 292 17. World Health Organization (WHO). Generic protocol A prospective cohort study investigating
293 maternal , pregnancy and neonatal outcomes for women and neonates infected with SARS-CoV-

- 294 2. 2020;(December).
- 295 18. Brasil. Presidência da República. Lei Geral de Proteção de Dados Pessoais (LGPD). Brasil: 2018.
- 296 19. Brasil. Conselho Nacional de Saúde. RESOLUÇÃO N° 510, DE 07 DE ABRIL DE 2016 O. 2016.
- 297 20. Craig AM, Hughes BL, Swamy GK. Expert Review Coronavirus disease 2019 vaccines in pregnancy.
298 Am J Obstet Gynecol MFM [Internet] 2021;3(2):100295. Available from:
299 <https://doi.org/10.1016/j.ajogmf.2020.100295>
- 300 21. Brasil. Ministério da saúde. secretaria de Vigilância em saúde. Boletim epidemiológico especial.
301 Doença pelo Novo Coronavírus – COVID-19 [Internet]. 2021. Available from:
302 [https://www.gov.br/saude/pt-](https://www.gov.br/saude/pt-br/media/pdf/2021/novembro/26/boletim_epidemiologico_covid_90_26nov21_eapv3b.pdf)
303 [br/media/pdf/2021/novembro/26/boletim_epidemiologico_covid_90_26nov21_eapv3b.pdf](https://www.gov.br/saude/pt-br/media/pdf/2021/novembro/26/boletim_epidemiologico_covid_90_26nov21_eapv3b.pdf)
- 304 22. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Situação epidemiológica dos
305 eventos adversos pós-vacinação contra a covid-19, Brasil, 2021. 2021;52.
- 306 23. Silva RB da, Silva TPR da, Sato APS, et al. Adverse events following immunization against SARS-
307 CoV-2 (covid-19) in the state of Minas Gerais. 2021;2:1–10.
- 308 24. Oliveira PMN de, Lignani LK, Conceição DA da, et al. O panorama da vigilância de eventos
309 adversos pós-vacinação ao fim da década de 2010: importância , ferramentas e desafios
310 Surveillance of adverse events following immunization in the late 2010s: an overview of the
311 importance , tools , and challenges El. 2020;
- 312 25. Gattás VL, Braga PE, Koike ME, et al. Safety assessment of seasonal trivalent influenza vaccine
313 produced by Instituto Butantan from 2013 to 2017. J São Paulo Inst Trop Med 2018;(November
314 2018):1–8.

- 315 26. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety
316 in Pregnant Persons. *N Engl J Med* 2021;384(24).
- 317 27. Riley LE. Editorial s mRNA Covid-19 Vaccines in Pregnant Women. 2021;2342–3.
- 318 28. Rodini ESO, Tsuribe PM, Maria L, Moreira V, Oliveira M De, Capannacci J. Abortamentos
319 espontâneos: estudos citogenéticos e riscos de recorrência Spontaneous abortions:
320 cytogenetic studies and risks of occurrence. 2004;11(1):50–2.
- 321 29. Zheng D, Li C, Wu T, Tang K. Factors associated with spontaneous abortion: a cross-sectional
322 study of Chinese populations. *Reprod Health [Internet]* 2017;14(1):33. Available from:
323 <http://reproductive-health-journal.biomedcentral.com/articles/10.1186/s12978-017-0297-2>
- 324 30. Fergusson DM, John Horwood L, Ridder EM. Abortion in young women and subsequent mental
325 health. *J Child Psychol Psychiatry [Internet]* 2006;47(1):16–24. Available from:
326 <https://onlinelibrary.wiley.com/doi/10.1111/j.1469-7610.2005.01538.x>
- 327 31. Cardoso BB, Saraceni V. Abortion in Brazil: what do the official data say? 2020;1–13.
- 328 32. Brasil. Ministério da Saúde. Manual de vigilância epidemiológica de eventos adversos pós-
329 vacinação. Brasília: 2021.
- 330 33. Silveira IO da, Silva TPR da, Oliveira BM, et al. Adverse events following immunization in pregnant
331 women from Minas Gerais. 2021;1–10.
- 332 34. Brasil. ANVISA. Plano de Monitoramento de Eventos Adversos de Medicamentos e Vacinas Pós-
333 Autorização de Uso Emergencial: Diretrizes e Estratégias de Farmacovigilância para o
334 enfrentamento da COVID-19. 2021.
- 335 35. Pacheco F, Domingues C, Maranhão A, et al. Análise do Sistema de Informação da Vigilância de

- 336 Eventos Adversos Pós-Vacinação no Brasil, 2014 a 2016. Rev Panam Salud Pública [Internet]
- 337 2018;1–8. Available from: <http://iris.paho.org/xmlui/handle/123456789/34861>
- 338

Tables

1
2 Table 1. Sociodemographic characteristics of pregnant and postpartum women that notified adverse events after receiving vaccines against
3 COVID-19

	Sinovac/Butantan		Pfizer/BioNTech		AstraZeneca ¹		Janssen		Total	
	AE (n= 187)	%	AE (n= 572)	%	AE (n= 1712)	%	AE (n= 15)	%	AE (n= 2,486)	%
<i>Age group (years old)</i>										
<15	0	0.0%	6	1.05%	5	0.29%	0	0.0%	11,00	0.44%
16 to 20	18	9.63%	76	13.29%	180	10.51%	2	13.33%	276,00	11.1%
21 to 25	47	25.13%	127	22.2%	460	26.87%	7	46.67%	641,00	25.78%
26 to 30	47	25.13%	101	17.66%	438	25.58%	3	20.0%	589,00	23.69%
31 to 35	51	27.27%	159	27.8%	398	23.25%	0	0.0%	608,00	24.46%
36 to 40	15	8.02%	68	11.89%	184	10.75%	0	0.0%	267,00	10.74%
41 to 45	8	4.28%	29	5.07%	20	1.17%	3	20.0%	60,00	2.41%
46 to 50	1	0.53%	1	0.17%	0	0.0%	0	0.0%	2,00	0.08%
>50	0	0.0%	5	0.87%	26	1.52%	0	0.0%	31,00	1.25%
Inconsistent ²	0	0.0%	0	0.0%	1	0.06%	0	0.0%	1,00	0.04%

Race/ethnicity

White	70	37.43%	222	38.81%	770	44.98%	3	20.0%	1065	42.84%
Black	12	6.42%	46	8.04%	80	4.67%	0	-	138	5.55%
Yellow	1	0.53%	2	0.35%	7	0.41%	0	-	10	0.4%
Brown	79	42.25%	220	38.46%	608	35.51%	10	66.67%	917	36.89%
Indigenous	1	0.53%	0	-	1	0.06%	0	-	2	0.08%
Ignored	24	12.83%	82	14.34%	246	14.37%	2	13.33%	354	14.24%

Region of notification

South	76	40.64%	162	28.32%	612	35.75%	3	20.0%	853	34.31%
Southeast	53	28.34%	260	45.45%	524	30.61%	3	20.0%	840	33.79%
North	14	7.49%	32	5.59%	70	4.09%	0	-	116	4.67%
Northeast	21	11.23%	90	15.73%	347	20.27%	7	46.67%	465	18.7%
Midwest	23	12.3%	28	4.9%	159	9.29%	2	13.33%	212	8.53%

Maternal situation

1st trimester	76	40.64%	173	30.24%	368	21.5%	13	86.67%	630	25.34%
2nd trimester	43	22.99%	144	25.17%	557	32.54%	2	13.33%	746	30.01%
3rs trimester	45	24.06%	163	28.5%	608	35.51%	0	-	816	32.82%
Postpartum	8	4.28%	12	2.1%	18	1.05%	0	-	38	1.53%
Inconsistent ³	10	5.35%	72	12.59%	136	7.94%	0	-	218	8.77%

Ignored⁴ 5 2.67% 8 1.4% 25 1.46% 0 - 38 1.53%

4 AE: Adverse Event; ¹AstraZeneca includes the vaccines ChAdOx1 nCoV-19 and BBV152; ²Ages unlikely to conceive a pregnancy were considered as inconsistent;

5 ³Gestational ages inconsistent with a pregnancy i.e.: 12 months ⁴Stated as ignored in the notification.

6 * Due to lack of notifications in the State of São Paulo, the Southeast region will include the States of Rio de Janeiro, Espírito Santo and Minas Gerais;

7

8 Table 2. Incidence of adverse events notified by Brazilian pregnant and postpartum women by vaccine received

	Overall				Pregnant				Postpartum			
	AE	N doses	IR*	95% CI	AE	N doses	IR*	95% CI	AE	N doses	IR*	95% CI
Sinovac/Butantan	187	252430	74.08	(63.47, 84.69)	179	193517	92.5	(78.95, 106.04)	9	58913	15.28	(5.3, 25.26)
Pfizer/BioNTech	572	484310	118.11	(108.43, 127.78)	560	372980	150.14	(137.72, 162.57)	12	111330	10.78	(4.68, 16.88)
AstraZeneca ¹	1712	65435	2616.34	(2494.04, 2738.64)	1694	37954	4463.3	(4255.55, 4671.04)	18	27481	65.5	(35.25, 95.75)
Janssen	15	1388	1080.69	(536.76, 1624.62)	15	367	4087.19	(2061.54, 6112.85)	0	1021	0	(0.0, 0.0)
Total	2486	803563	309.37	(297.23, 321.51)	2448	604818	404.75	(388.75, 420.75)	39	198745	19.62	(13.47, 25.78)

9 AE: Adverse Events; IR: incidence rate; CI: Confidence interval;

10 * IR per 100,00 doses; ¹AstraZeneca includes the vaccines ChAdOx1 nCoV-19 and BBV152;

11 N.B: Pregnant women can be breastfeeding; hence, they will count in pregnant and postpartum columns.

12 Table 3. Incidence of AE among pregnant women according to the type and severity

	Sinovac/Butantan		Pfizer/BioNTech		AstraZeneca ¹		Janssen		Total	
	IR*	95% CI	IR*	95% CI	IR*	95% CI	IR*	95% CI	IR*	95% CI
Maternal	10.3	(6.34, 14.26)	9.7	(6.93, 12.48)	65.71	(46.08, 85.35)	72.05	(0.0, 213.2)	14.56	(11.92, 17.2)
Systemic	50.31	(41.56, 59.06)	89.41	(80.99, 97.82)	2194.5	(2082.29, 2306.8)	864.55	(377.51, 1351.59)	249.88	(238.97, 260.8)
Local	4.36	(1.78, 6.93)	15.49	(11.98, 18.99)	311.76	(269.05, 354.47)	144.09	(0.0, 343.65)	36.34	(32.17, 40.51)

13 IR: incidence rate; CI: confidence interval; ¹AstraZeneca includes the vaccines ChAdOx1 nCoV-19 and BBV152;

14 *IR per 100,000 doses administered.

15 Table 4. Frequency of most common adverse events experienced by pregnant and postpartum women receiving COVID-19 vaccines and who
16 reported an AEFI

	Sinovac/Butantan		Pfizer/BioNTech		AstraZeneca ¹		Janssen		Total	
	AE	%	AE	%	AE	%	AE	%	AE	%
	(n= 187)		(n= 572)		(n= 1712)		(n= 15)		(n=2,486)	
Maternal										
Spontaneous abortion	9	4.81%	28	4.9%	21	1.23%	1	0.066%	59	2.37%
Pregnancy bleeding	6	3.21%	3	0.52%	11	0.64%	0	0%	20	0.80%
Neonatal death	3	1.6%	9	1.57%	1	0.06%	0	0%	13	0.52%

Premature birth	1	0.53%	3	0.52%	3	0.18%	0	0%	7	0.28%
Abdominal pregnancy	3	1.6%	0	0%	0	0%	0	0%	3	0.12%
<i>Non-maternal</i>										
Headache	20	10.7%	77	13.46%	360	21.03%	4	28.57%	461	18.54%
Fever	13	6.95%	46	8.04%	282	16.47%	2	14.29%	343	13.8%
Myalgia	12	6.42%	37	6.47%	206	12.03%	1	7.14%	256	10.3%
Pain	3	1.6%	35	6.12%	149	8.7%	2	14.29%	189	7.6%
Vomit	2	1.07%	20	3.5%	67	3.91%	2	14.29%	91	3.66%
Chills	4	2.14%	8	1.4%	77	4.5%	0	0%	89	3.58%
Nausea	2	1.07%	19	3.32%	62	3.62%	1	7.14%	84	3.38%
Abdominal pain	9	4.81%	22	3.85%	44	2.57%	1	7.14%	76	3.06%
Diarrhea	3	1.6%	20	3.5%	40	2.34%	0	0%	63	2.53%
Arm Pain	0	0%	26	4.55%	34	1.99%	0	0%	60	2.41%
Asthenia	6	3.21%	15	2.62%	35	2.04%	0	0%	56	2.25%
Fatigue	2	1.07%	14	2.45%	39	2.28%	0	0%	55	2.21%
Cough	7	3.74%	28	4.9%	17	0.99%	0	0%	52	2.09%
Dyspnea	5	2.67%	15	2.62%	31	1.81%	0	0%	51	2.05%
Runny nose	7	3.74%	23	4.02%	16	0.93%	0	0%	46	1.85%
Sore throat	4	2.14%	11	1.92%	22	1.29%	0	0%	37	1.49%

Edema	4	2.14%	9	1.57%	14	0.82%	0	0%	27	1.09%
-------	---	-------	---	-------	----	-------	---	----	----	-------

17 AE: Adverse event; ¹AstraZeneca includes the vaccines ChAdOx1 nCoV-19 and BBV152.

18

Figures

1

2

3 Figure 1. Attrition diagram

